Ocular Therapeutix (OCUL) Other Non-Current Assets (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Other Non-Current Assets of $1.6 million for Q2 2026, up 7.6% year-over-year from $1.5 million in Q2 2025, and little changed on a QoQ basis from $1.6 million in Q1 2026.
Ocular Therapeutix (OCUL) Other Non-Current Assets (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Other Non-Current Assets for 14 years, with the latest figure at $1.6 million in Q2 2026.
- Other Non-Current Assets for Q2 2026 came in at $1.6 million, up 7.6% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.6 million (up 7.6% YoY), and the FY2025 annual result was $1.6 million, changed 0.0% from the prior year.
- Other Non-Current Assets was little changed at $1.6 million in Q2 2026, from $1.6 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $1.8 million in Q1 2022 and troughed at $1.5 million in Q2 2025.
- A 5-year average of $1.7 million and a median of $1.6 million in 2023 frame the typical range for Other Non-Current Assets.
- The widest annual swing landed in 2023, when Other Non-Current Assets declined 8.5%; it then increased 7.6% in 2026.
- A 5-year view of Other Non-Current Assets shows it stood at $1.8 million in 2022, then declined by 8.5% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then changed by 0.0% to $1.6 million in 2025, then changed by 0.0% to $1.6 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Assets figures were $1.6 million in Q2 2026, $1.6 million in Q1 2026, and $1.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn | 1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.61 Mn |
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 1.61 Mn |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 1.61 Mn |
| Mar 31, 2025 | 1.61 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.61 Mn |
| Jun 30, 2024 | 1.61 Mn |
| Mar 31, 2024 | 1.61 Mn |
| Dec 31, 2023 | 1.61 Mn |
| Sep 30, 2023 | 1.76 Mn |
| Jun 30, 2023 | 1.76 Mn |
| Mar 31, 2023 | 1.76 Mn |
| Dec 31, 2022 | 1.76 Mn |
| Sep 30, 2022 | 1.76 Mn |
| Jun 30, 2022 | 1.76 Mn |
| Mar 31, 2022 | 1.76 Mn |
| Dec 31, 2021 | 1.76 Mn |
| Sep 30, 2021 | 1.76 Mn |